YLYang Li

Yang Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yang Li has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Chaogang Fan

    Research Institute of General Surgery, Jinling Hospital, School of Medicine, Nanjing University, 305 Zhongshan Eastern road, 210002 Nanjing, China

    1 shared publication
  • Deliang Yu

    Division of Digestive Surgery, Xijing Hospital, Fourth Military Medical University, 127, West Changle road, 710032 Xi'an, Shaanxi, China

    1 shared publication
  • Guoli Li

    Research Institute of General Surgery, Jinling Hospital, School of Medicine, Nanjing University, 305 Zhongshan Eastern road, 210002 Nanjing, China

    1 shared publication
  • Guoli Li

    Research Institute of General Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, People’s Republic of China

    1 shared publication
  • Jieshou Li

    Research Institute of General Surgery, Jinling Hospital, School of Medicine, Nanjing University, 305 Zhongshan East Road, Nanjing 210002, China.

    1 shared publication
  • Long Ma

    Research Institute of General Surgery, Jinling Hospital, School of Medicine, Nanjing University, No.305 East Zhongshan Road, Nanjing, 210002, China

    1 shared publication

Latest Publications

  • Open Access

    A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis

    by Qi He, Long Ma, Yang Li, Guoli Li

    The incidence of the para-aortic lymph node metastasis (PALM) in patients with advanced gastric cancer is 6 to 33 %. The prognosis is poor and the 5-year survival rate is only 12 to 23 % after gastrectomy with super-extended lymph node dissection. We applied an individualized comprehensive treatment for affected patients including neoadjuvant chemotherapy via intra-arterial and intravenous administration, surgery and radiotherapy, to investigate the safety and prognostic value. Between January 2005 and December 2010, 47 advanced gastric cancer patients with PALM received 5-Fu (370 mg/m2) and leucovorin (200 mg/m2) intravenously on days 1–5, and intra-arterial infusion of etoposide (80 mg/m2) and oxaliplatin (80 mg/m2) on days 6 and 20, repeated 2 cycles. Patients achieved PR or CR of the para-aortic lymph node (PAL) were performed D2 dissection, followed by 6 cycles chemotherapy with XELOX regimen, oxaliplatin (130 mg/m2) on day 1 and xeloda (1000 mg/m2) on days 1 to 14 of a 28-day cycle, and radiotherapy to the region of PALM. Forty-six patients completed 2 cycles of neoadjuvant chemotherapy. The overall response rate of the primary tumor was 80.4 % (37/46). The response rate of PAL was 76.1 % (35/46). Thirty-two patients underwent D2 dissection and six cases achieved pathological complete response (pCR). The toxicity profile was well tolerable and there was no treatment-related death. The median survival time for all patients was 23 months, and for nonsurgical and surgical patients were 12 and 29 months (p < 0.001), respectively. The 1-year, 2-year and 3-year survival rate was 70.96, 43.27 and 35.48 % for all patients, and for surgical patients was 96.875, 68.75, and 40.63 %. Advanced gastric cancer patients with PALM can obtain a survival benefit from neoadjuvant chemotherapy, subsequent surgery and radiotherapy. Current Controlled Trials ChiCTR-TRC-12002046 .


  • Open Access

    The study of n-3PUFAs protecting the intestinal barrier in rat HS/R model

    by Yang Li, Xinying Wang, Ning Li, Jieshou Li

    N-3 PUFAs have been demonstrated in vitro it could prevent the intestinal tight junctions (TJs) from the ischemia/re-perfusion injury and the inflammatory reaction injury. The purpose of this study was to evaluate the protection of n-3 PUFAs on the intestinal TJs in the rat model of hemorrhagic shock followed by resuscitation. Male SD rats (n = 72; 250 ~ 300 g) were randomly divided into 6 groups: SHAM, hemorrhagic shock (HS), hemorrhagic shock/resuscitation (HS/R), ω-6 group, ω-3 group and ω-3 treatment group. Shock was induced, and a mean arterial pressure was maintained at 35 to 40 mmHg for 60 minutes. Resuscitation was carried out by returning half of the shed blood and Ringer’s lactate solution. In ω-6 and ω-3 group, Intralipid or fish oil (0.2 g/Kg), respectively, was infused 30 minutes after shock. And fish oil was infused with resuscitation in ω-3 treatment group. Half of each group was killed at 30 minutes and 4 hours after resuscitation, respectively. The serum samples and the intestinal sample was collected for further examination. There is no difference between ω-3, ω-3 treatment and sham group in Chiu’s score, but the other three groups have higher scores than they did. Compared with HS, HSR and ω-6 group, ω-3 and ω-3 treatment group showed most intact in intestinal mucoscal villi and TJs through HE, SEM and LSCM. The levels of IL-6 and TNF-α of bowel tissue in ω-3 and ω-3 treatment group were significantly lower than HS and HSR groups’. At the time point of 30 min, the levels of serum endotoxin were dramatically higher in HS、HSR and ω-6 groups when compared with ω-3, ω-3 treatment and sham group. However, it in ω-3 group was greater than sham and HS group until 4 hours. Fish oil pretreatment before resuscitation showed a beneficial effect to the intestinal TJs and atteunated inflammation after H/R in HS/R rat model and is better than ω-6 PUFAs did.